Bristol-Myers Squibb (BMY) got some exciting news from a study on experimental drug ipilimumab. The study concluded that the drug was effective at bolstering the immune system of patients with advanced melanoma, although some side effects were severe. On average the trial improved life spans of these patients by about four months, a major difference by all accounts. Bristol-Myers plans to file ap
Stocks News » Healthcare Industry
Bristol-Myers Stock Upgraded
Posted by richardalwin 93 days ago (http://seekingalpha.com)
In contrast to Amgen, AstraZeneca suffered three pipeline setbacks. The firm failed to win a U.S. panel’s backing to introduce an improved version of its $1 billion-a-year medicine to prevent a respiratory disease that sends 125,000 babies to hospitals each year, reported Bloomberg News.
Advisers to the Food and Drug Administration (FDA) recommended against approval of Motavizumab for children
Advisers to the Food and Drug Administration (FDA) recommended against approval of Motavizumab for children
CIGNA's Strong Performance Reaffirms 2010 Outlook
Posted by xiulian 213 days ago (http://seekingalpha.com)
CIGNA Corporation’s (CI) fourth quarter operating earnings of $1.03 per share were ahead of the Zacks Consensus Estimate of 96 cents. The company had earned 48 cents a share in the year-ago period.
The results reflect the improvements in the equity market that aided in its reinsurance business performance. Additionally, the results were also strong in its accident insurance business.
The results reflect the improvements in the equity market that aided in its reinsurance business performance. Additionally, the results were also strong in its accident insurance business.
How Big Pharmarceutical Companies Got in This Fix
Posted by xiulian 213 days ago (http://seekingalpha.com)
.Still significant value in Pharma - we see material upside to ROIC [return on invested capital], earnings and multiples as Pharma withdraws from most internal small-molecule research and reallocates capital to in-licensing and other non-pharma assets. Worsening generic pressure and R&D management changes lead us to expect material cuts to internal small research spend (~40% total R&D) in 2010/11
GSK to announce more than 3,000 job cuts
Posted by SHPark 219 days ago (http://www.ft.com)
GlaxoSmithKline will this week announce reduced investment in some disease areas and more than 3,000 job cuts as it intensifies its diversification away from its core pharmaceutical business.
The action – to be announced with its annual results on Thursday – follows a much larger restructuring last week by AstraZeneca, with 8,000 jobs losses as part of a $2bn (£1.3bn) five-year restructuring.
The action – to be announced with its annual results on Thursday – follows a much larger restructuring last week by AstraZeneca, with 8,000 jobs losses as part of a $2bn (£1.3bn) five-year restructuring.
QLT's Attractive Risk / Reward Profile
Posted by JeffPalen 222 days ago (http://seekingalpha.com)
QLT, Inc. (QLTI) will look to some like a failed pharmaceutical company with only one drug on the market, the sales of which have dropped almost 80% over the past 4 years. I propose another perspective: a small biotech with huge amounts of cash, one product on the market covering most of their expenses, a promising pipeline, plus enough past successes to suggest they can bring some more drugs out
McKesson Corporation: One of the Best Healthcare Stocks to Own
Posted by JeffPalen 222 days ago (http://seekingalpha.com)
McKesson Corporation (MCK) has one the strongest fundamental profiles in the Healthcare Sector and, in our opinion, is one of the best healthcare stocks to own at the current moment. Our view is supported on a detailed DCF scenario analysis and valuation relative to its history and peers.
Restructuring charges push J&J net down 19%
Posted by Patsky 225 days ago (http://www.marketwatch.com)
Johnson & Johnson Tuesday reported a 19% fall in fourth-quarter profit, due largely to hefty restructuring charges.
For the fourth-quarter, the health-care products conglomerate posted net income of $2.21 billion, or 79 cents a share, compared with $2.71 billion, or 97 cents a share, for the 2008 period.
For the fourth-quarter, the health-care products conglomerate posted net income of $2.21 billion, or 79 cents a share, compared with $2.71 billion, or 97 cents a share, for the 2008 period.
Resources
If you want to improve your currency trading knowledge, eToro has all the information needed for your FX trading education. The site offers tutorials and support for newbie traders.
Open your real Forex trading account with Forex Club.
Find the best Credit Card offers online.
Contacts - For the best prices in contact lenses including Acuvue, Biomedics, Focus, Frequency, FreshLook, O2/Air Optix, Proclear, PureVision, SofLens, Vertex contact lenses as well as other major brands of contact lenses.